Progressive MS Study Links T-Cell Signatures to Cognitive Outcomes
KEY TAKEAWAYS
- Vidofludimus calcium treatment was associated with fewer Epstein-Barr virus-specific T-cell receptor signatures in patients with progressive MS in a post hoc analysis of the phase 2 CALLIPER trial.
- Reductions in EBV-specific T-cell receptor signatures were associated with improved cognitive performance on the SDMT.
- The association between reduced EBV-specific signatures and cognitive improvement was most apparent in patients with primary progressive MS.
Vidofludimus calcium (Immunic, Gräfelfing, Germany), an investigational treatment, was associated with reductions in Epstein-Barr virus (EBV)-specific T-cell receptor (TCR) signatures in individuals with progressive multiple sclerosis (MS), according to a post hoc analysis of results of the phase 2 CALLIPER trial (NCT05054140) presented at the 2026 Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026). Reductions in EBV-specific TCR signatures were also associated with improved cognitive performance, particularly among individuals with primary progressive MS (PPMS), suggesting a relationship between EBV-related immune activity and cognitive outcomes.
CALLIPER was a randomized, placebo-controlled phase 2 trial evaluating treatment with vidofludimus calcium, an oral direct activator of nuclear receptor-related 1 (Nurr1) and selective dihydroorotate dehydrogenase (DHODH) inhibitor. In this post hoc analysis, investigators performed TCR beta-chain sequencing on 206 blood samples from 87 participants, evaluating EBV-specific and influenza A-specific TCR sequence matches from baseline through week 48. Baseline and placebo samples were grouped as untreated and compared with samples collected during vidofludimus calcium treatment. Investigators also examined associations between changes in viral-specific TCR signatures and clinical outcomes, including cognitive performance measured on the Symbol Digit Modalities Test (SDMT).
Findings from the Analysis of the Phase 2 CALLIPER Trial
- EBV-specific immune signatures: Vidofludimus calcium treatment was associated with fewer major histocompatibility complex class I-restricted EBV-specific TCR matches compared with untreated samples (difference, −0.65 matches; P=.0004).
- Influenza A comparison: Influenza A-specific TCR matches did not differ significantly between treatment conditions (difference, +0.08 matches; P=.5983).
- Cognitive performance: Across both treatment arms, reductions in EBV-specific TCR matches were associated with improved SDMT scores (12.14-point improvement per match reduction; P=.0302).
- PPMS subgroup: Among 31 patients with PPMS, reductions in EBV-specific TCR matches were associated with improved SDMT scores (14.01 points per match reduction; P=.0499).
- Secondary progressive MS: No corresponding association was observed among 27 patients with nonactive secondary progressive MS (P=.6264).
Source
Schreieck A, Schneider-Hohendorf T, Ondruš M, et al. Anti-EBV T-cell receptor repertoire reduction is linked to enhanced cognitive performance in progressive multiple sclerosis: evidence from the phase 2 CALLIPER trial with vidofludimus calcium, a direct Nurr1 activator and selective DHODH inhibitor. Abstract 1203. Presented at: 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026); October 21–23, 2026; Toronto, Ontario, Canada.